目的比较两种抗病毒药物治疗肝硬化的疗效。方法选取50例乙肝肝硬化患者,随机分为三组:阿德福韦酯组12例、恩替卡韦组18例,对照组20例。对照组给予常规保肝对症治疗,其余两组在保肝基础上分别接受阿德福韦酯10mg/d,恩替卡韦0.5mg/d口服,对比三组治疗前后肝功能,乙肝病毒定量,Child-Pugh分级评分的变化。结果治疗48周后,恩替卡韦组和阿德福韦酯组在治疗前后肝功能明显改善(P<0.05),对照组肝功能治疗前后无差异(P>0.05),恩替卡韦组和阿德福韦酯组肝功能在治疗后好于对照组(P<0.05),但是它们之间无差异(P>0.05)。恩替卡韦组转阴率12周94.44%、24周94.44%、48周100%;阿德福韦酯组转阴率12周41.67%、24周83.33%、48周91.67%;对照组治疗前后无差异,转阴率均为0%。在12周时,恩替卡韦组转阴率高于阿德福韦酯组(P<0.05);Child-Pugh分级评分对照组治疗后评分升高,阿德福韦酯和恩替卡韦组均有下降,但是三组前后没有显著性差异(P>0.05)。结论阿德福韦酯及恩替卡韦抗病毒后,患者病毒量下降,肝功能改善,ChildPugh评分下降,对肝硬化的治疗有积极的作用,恩替卡韦组相对抗病毒疗效更好。 Objective To compare the efficacy of two antiviral drugs in the treatment of liver cirrhosis. Methods Fifty patients with hepatitis B cirrhosis were randomly divided into three groups: 12 in adefovir dipivoxil group, 18 in entecavir group and 20 in control group. The control group received routine hepatoprotective symptomatic treatment. The other two groups received adefovir dipivoxil 10 mg / d and entecavir 0.5 mg / d respectively on the basis of liver protection. The liver function, hepatitis B virus quantification, Child-Pugh Changes in graded scores. Results After 48 weeks treatment, the liver function of entecavir group and adefovir dipivoxil group were significantly improved before and after treatment (P <0.05), while no significant difference was found between the control group before and after hepatic function (P> 0.05). Entecavir group and adefovir dipivoxil Compared with the control group, liver function was better in the control group (P <0.05), but there was no difference between them (P> 0.05). The rate of negative conversion in entecavir group was 94.44% at 12 weeks, 94.44% at 24 weeks and 100% at 48 weeks. The negative conversion rate of adefovir was 41.67% at 12 weeks, 83.33% at 24 weeks and 91.67% at 48 weeks. There was no difference in the control group before and after treatment , The negative rate of 0%. At 12 weeks, the rate of negative conversion to entecavir was higher than that of adefovir dipivoxil (P <0.05); Child-Pugh grading score increased in the control group after treatment, but both adefovir dipivoxil and entecavir decreased Three groups before and after no significant difference (P> 0.05). Conclusion Adefovir dipivoxil and entecavir anti-virus, the patient’s viral load decreased, improved liver function, ChildPugh score decreased, the treatment of cirrhosis have a positive effect, the relatively anti-virus entecavir group better.